Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is about treating people who have a type of cancer called multiple myeloma that has come back. The doctors want to see if using drugs called chemotherapy, combined with an immune system treatment, can help. They will give patients a treatment that includes different drugs that can stop the cancer from growing and spreading. Then they will give the patients a donor stem cell transplant, which can also help fight the cancer. The doctors hope this treatment will make the cancer go away and that it won't come back.
This study is about treating people who have a type of cancer called multiple myeloma that has come back. The doctors want to see if using drugs called chemotherapy, combined with an immune system treatment, can help. They will give patients a treatment that includes different drugs that can stop the cancer from growing and spreading. Then they will give the patients a donor stem cell transplant, which can also help fight the cancer. The doctors hope this treatment will make the cancer go away and that it won't come back.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase II trial studies how well a reduced intensity conditioning regimen after donor stem cell transplant works in treating patients with multiple myeloma that has come back (relapsed). Drugs used in chemotherapy, such as cyclophosphamide, tacrolimus, and mycophenolate mofetil, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving a reduce intensity conditioning regimen consisting of cyclophosphamide, tacrolimus, mycophenolate mofetil, and daratumumab after donor stem cell transplant may improve survival and reduce the risk of multiple myeloma coming back.
This phase II trial studies how well a reduced intensity conditioning regimen after donor stem cell transplant works in treating patients with multiple myeloma that has come back (relapsed). Drugs used in chemotherapy, such as cyclophosphamide, tacrolimus, and mycophenolate mofetil, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving a reduce intensity conditioning regimen consisting of cyclophosphamide, tacrolimus, mycophenolate mofetil, and daratumumab after donor stem cell transplant may improve survival and reduce the risk of multiple myeloma coming back.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: